1Research on the evaluation system for drug venture capital based on clinical valueWU Xia, YANG Ting-ting, SHAO Rong2281-22852Research on incentive system of innovative drug R&D from the perspective of venture capitalWU Xia, SHAO Rong2286-22933Overview of accelerated approval by US FDA and some reference points for ChinaZHAO Chen-yang, WANG Hong-hang, HUANG Yun-hong, YANG Huan, GAO Chen-yan2294-23024Advances in oral delivery technology of drug cocrystalsFENG Yu-miao, LIU Mei, HUANG Bi-yao, YANG Mei-yan2303-23085Research progress of cardiotoxicity induced by targeted cancer therapiesZHANG Yi-zhe, WANG Mei-ting, ZHAO Qi, XING Hong-yan, ZHOU Jie, QIAO Ying, WANG Xi-jie2309-23146Embolism risk following systemic intravascular administration of mesenchymal stem cells in preclinical and clinical studiesWANG Yan, LI Hua, TANG Na-ping, WEI Li-ping, MA Jing2315-23207Advances in research on the mechanism of IKKα and IKKβ signaling pathways in tumors and related drugsZHOU Yong-ming, HUANG Wei-qi, JIANG Gao-feng, NI Jian, YU Mei-xia2321-23308Advances in research on anti-tuberculosis natural small moleculesWANG Ren-feng, AN Ting-ting, JIANG Chang-he, ZHOU Lei, YANG Zai-chang2331-23409Research progress in drugs for prevention and treatment of inner ear diseasesWU Ai-xin, YE Rui-qin, WEN Lu, CHEN Gang2341-235010Research progress of anlotinib-induced hypertensionZHANG Li, XING Ya-qun, JIANG Jie-mei, XIA Quan2351-235711Progress in synthesis of ursodeoxycholic acid from chenodeoxycholic acidGUO Meng-qin, ZHANG Yi-ming, WANG Hong-lu, GUO Peng2358-236312Construction of precise competency model for clinical inspectors in China based on the empirical research of three types of expertsXU Yang-yan, WU Fang, YU Qian, YANG Jian-hong, WANG Fang-min, Zhang Yan-yan2364-237113Investigation on molecular mechanism of ursolic acid in the treatment of gastric cancer based on network pharmacology and molecular dockingFANG Chong-kai, YANG Li-ting, MO Zong-quan, GUAN Jie-shan, XIAO Zhi-wei, HUANG Xue-wu, LIN Li-zhu, CHEN Zhuang-zhong2372-238014Pharmacodynamics of neptinib based on the human-derived tumor xenograft (PDX) model of lung adenocarcinomaZHANG Chen, ZHANG Yu, WANG Chun-yu, LI Wei, CI Xiao-yan, WU Wei-dang, ZENG-Yong, SU Yan-jun, CUI Tao, YIN Xiu-lin, YAN Feng-ying2381-238815Pirfenidone for the treatment of idiopathic pulmonary fibrosis:a rapid health technology assessmentDONG Xiu, XIE Ran, LI Ruo-ming, TIAN Xin, WANG Zi-ning, ZHOU Ying, CUI Yi-min2389-239416Cardiovascular toxicity report of taxanes and its literature analysisCHEN Su-hua, LIU Hong, ZHANG Yan-hua2395-2400 